TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00150748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 166 mg
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 166 mg~* Route of Administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 250 mg
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 250 mg~* Route of Administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 500 mg
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 500 mg~* Route of Administration: Oral use
Study: NCT03359837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection
Study: NCT01103973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind/Body Program
Description: Ten week group mind/body program

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Spa gift certificates
Study: NCT03359837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic insulin aspart 30
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Pharmaceutical form: tablet~Route of administration: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Pharmaceutical form: tablet~Route of administration: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: tablet or capsule~Route of administration: oral administration
Study: NCT00914836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Sodium Phosphate
Description: 1cc:2cc
Study: NCT04126486

Intervention type: OTHER
Group type: OTHER
Intervention: Zio®XT Monitor
Description: A Zio® XT monitor will be affixed to the participant's chest
Study: NCT00914836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Sodium Phosphate
Description: 1cc:2cc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 cc - Betamethasone Sodium Phosphate
Description: Betamethasone Sodium Phosphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 cc - Betamethasone Sodium Phosphate
Description: Betamethasone Sodium Phosphate
Study: NCT02417233

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS text message
Description: bi-weekly behavioral messages and bi-weekly check-in messages

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS text message + Peer Navigation
Description: bi-weekly behavioral messages plus personalized peer navigation
Study: NCT04184999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone intraocular suspension, 9%
Description: single dose intracameral corticosteroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Acetate 1% Oph Susp
Description: topical ophthalmic steroid drop

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate 1% Oph Susp
Description: topical ophthalmic steroid drop
Study: NCT01008384

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 50,000 units taken orally once a week for 8 weeks
Study: NCT01745354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: SD-101 will be administered after radiation to only the largest palpable lymph node as an intratumoral injection weekly for 3 weeks at three dosing cohorts: 0.3 mg, 1 mg, and 3 mg

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local Radiation
Study: NCT03662256

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current Primary Care Referral Process
Description: Children who refer hearing screening will receive the same referral method each preschool had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine Referral Process
Description: In communities randomized to the expedited telemedicine intervention, parents of children who refer hearing screening will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children who refer screening will be transported to clinic for their appointment with adult chaperones. Parent participation will be required unless parents direct otherwise. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
Study: NCT00680069

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005
Description: Inactivated monovalent subvirion influenza A/H5N1/Indonesia/05/05 (clade 2) vaccine administered via intramuscular injection. Low Dose Group will receive 15 mcg intramuscularly (IM), High Dose Group will receive 90 mcg IM. Subjects who received previous clade 1 vaccine will receive 1 dose, clade 1 vaccine-naive subjects will receive 2 doses 28 days apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005
Description: Inactivated monovalent subvirion influenza A/H5N1/Indonesia/05/05 (clade 2) vaccine administered via intramuscular injection. Low Dose Group will receive 15 mcg intramuscularly (IM), High Dose Group will receive 90 mcg IM. Subjects who received previous clade 1 vaccine will receive 1 dose, clade 1 vaccine-naive subjects will receive 2 doses 28 days apart.
Study: NCT03185182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ioflupane I123
Description: 185 MBq ioflupane I123 will be administered at one single occasion to the study subjects A one time dose of DaTSCAN is given via intravenous injection of 185 MBq Ioflupane (I123) .~The patient takes potassium iodine tablets prior to the DatSCAN injection to protect the thyroid gland. At the time of the DaTSCAN examination, the patient is injected intravenously at slow rate with 185MBq DaTSCAN solution.
Study: NCT01353846

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: observation natural cycle
Description: The patients natural reproductive cycle will be observed and compared to the second arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Agonist GnRH; estradiol Valerate; progesterone
Description: Medications: Agonist GnRH Acetate Triptoreline and Acetate Triptorelina and Estradiol Valerate and Natural micronized progesterone, 400 mg/12 hours vaginal administration
Study: NCT06133218

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mepitel Film
Description: A safetac-based barrier film with a clinically insignificant bolus effect to protect the skin during radiotherapy.
Study: NCT01660022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg OZ439 single oral dose
Description: 100mg OZ439 oral suspension single dose
Study: NCT01465698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The main target for exercise intervention is to restore impairments in movement control. First, the participants need to learn the proper technique of each exercise, second to achieve movement control of lumbar neutral zone in each exercise, and finally to increase the challenge of exercises for balance, coordination, muscular endurance and strength. Target dose for exercise is twice a week, 60 minutes per session for six months.~The neuromuscular exercise program is progressive including three different performance levels. During the first eight weeks, the supervised exercise sessions will take place twice a week. The next 16 weeks the participants have one instructed weekly session, and they exercise once a week at home with help of a DVD or booklet produced for the study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Counseling is conducted according cognitive-behavioral principles. Fear-avoidance model is implemented using problem based learning. The objective is to change participants' understanding of LBP towards less fearful and negative beliefs, and to provide encouragement for usual daily activities, including physical activity. Advice on nursing tasks that are strenuous for low back is aimed to improve awareness of injury risk and provide examples of proper postures and movements. The target is that participants in counseling groups attend 10 sessions each lasting 45 minutes. During the first four weeks the groups meet every second week, and after that once a month up to six months. Participants will receive workbooks to enhance problem-based learning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and counseling
Description: Participants take part in both exercise and counseling as described in the separate interventions.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Participants in the control group take part only in measurements of NURSE-RCT.
Study: NCT05337813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Storz Medical Extracoporeeal Shock Wave Therapy System
Description: A. B. C. D. groups need to Low Energy Extracorporeal Shock Wave (LiESWT) therapy once a week, duration 8 weeks(B.、C. groups needs to be combined PRP treatment at 1, 5, 9 weeks)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Storz Medical Extracoporeeal Shock Wave Therapy System
Description: A. B. C. D. groups need to Low Energy Extracorporeal Shock Wave (LiESWT) therapy once a week, duration 8 weeks(B.、C. groups needs to be combined PRP treatment at 1, 5, 9 weeks)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Storz Medical Extracoporeeal Shock Wave Therapy System
Description: A. B. C. D. groups need to Low Energy Extracorporeal Shock Wave (LiESWT) therapy once a week, duration 8 weeks(B.、C. groups needs to be combined PRP treatment at 1, 5, 9 weeks)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Storz Medical Extracoporeeal Shock Wave Therapy System
Description: A. B. C. D. groups need to Low Energy Extracorporeal Shock Wave (LiESWT) therapy once a week, duration 8 weeks(B.、C. groups needs to be combined PRP treatment at 1, 5, 9 weeks)
Study: NCT06503861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Is Medicine intervention
Description: The intervention provides regular meal kits as well as cooking and nutritional education.
Study: NCT01228513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZK245186
Description: Daily topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZK245186
Description: Daily topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZK245186
Description: Daily topical application
Study: NCT01660022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg OZ439 single oral dose
Description: 100mg OZ439 oral suspension single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg OZ439 single oral dose
Description: 100mg OZ439 oral suspension single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg OZ439 single oral dose
Description: 100mg OZ439 oral suspension single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg OZ439 single oral dose
Description: 300mg OZ439 oral suspension single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg OZ439 single oral dose
Description: 300mg OZ439 oral suspension single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 160mg Piperaquine single oral dose
Description: 160 mg Piperaquine tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 480mg Piperaquine single oral dose
Description: 480 mg Piperaquine tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1440mg Piperaquine single oral dose
Description: 1440 mg Piperaquine tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1440mg Piperaquine single oral dose
Description: 1440 mg Piperaquine tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1440mg Piperaquine single oral dose
Description: 1440 mg Piperaquine tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 mg OZ439 single oral dose
Description: 800mg OZ439 oral suspension single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 mg OZ439 single oral dose
Description: 800mg OZ439 oral suspension single dose
Study: NCT05659524

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal saline irrigation
Description: The following nasal care recommendations have been approved by the study protocol committee for patients randomized to the treatment arm with saline irrigations:~* Postoperative days 1 through 3: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily.~* Postoperative day 3 to week 12: patients will begin twice daily sinus irrigation rinse (e.g., NeilMed Sinus Rinse). They will perform 240 mL sinus rinses BID. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
Study: NCT04464109

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Evisceration with orbital implantation
Description: Evisceration will be performed. Alloplastic orbital implant will be inserted either posterior to the sclera or partly within the scleral canal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Evisceration with orbital implantation
Description: Evisceration will be performed. Alloplastic orbital implant will be inserted either posterior to the sclera or partly within the scleral canal.
Study: NCT00612677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Dose Regimen: 120 mg/m\^2 on Days 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Dose Regimen: 500 mg/m\^2 on Days 1 every 21 days
Study: NCT01473147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide 5 microgram bid sc.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 2 u bid sc.
Study: NCT01118026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABVD
Description: doxorubicin 25 mg/m\^2 IV bleomycin 10 units/m\^2 IV vinblastine 6 mg/m\^2 IV dacarbazine 375 mg/m\^2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEACOPP
Description: bleomycin 10 units/m\^2 IV on Day 8 etoposide 200 mg/m\^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m\^2 IV on Day 1 cyclophosphamide 1250 mg/m\^2 IV on Day 1 vincristine 1.4 mg/m\^2 IV on Day 8 procarbazine 100 mg/m\^2 orally on Days 1-7 prednisone 40 mg/m\^2 orally on Days 1-14

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02428582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covered stent (Atrium Type V12)
Description: An endovascular treatment that consists of inserting a covered stent into the stenosed vessels.
Study: NCT01228513

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle without active ingredient)
Description: Daily topical application
Study: NCT02428582

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare stent (Brand Cordis Type Palmaz Blue)
Description: An endovascular treatment that consists of inserting a stent into the stenosed vessels.
Study: NCT01328912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning stimulus
Description: The intervention will consist of 3 cycles of 5 minutes of upper limb ischemia. The RIPC stimulus will be performed using a blood pressure cuff placed on the upper arm inflated above systemic pressure to 200 mmHg for 5 minutes, then deflated for 5 minutes. Ischemia will be assured with the use of a saturation probe on the digit of the involved arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: These patients are randomized to placebo, thus they will no undergo the RIPC stimulus.
Study: NCT01272089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
Description: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once a day for one week
Study: NCT04285762

Intervention type: OTHER
Intervention: LVEEA
Description: lymphaticovenous end-to-end

Intervention type: OTHER
Intervention: LVESA
Description: lymphaticovenous end-to-side

Intervention type: OTHER
Intervention: LVSEA
Description: lymphaticovenous side-to-end
Study: NCT02920359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEUPRORELIN ACETATE
Study: NCT00414206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mecamylamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mecamylamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00919763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD2027 Ointment 3 mcg/g, twice daily
Description: Topical Ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ointment, twice daily
Description: Topical Ointment
Study: NCT02008253

Intervention type: PROCEDURE
Intervention: INTRASTROMAL CORNEAL RING SEGMENT
Description: Corneal tunnels were created by means of mechanical dissection in all eyes. Main outcome measures included UCVA, BCVA, refraction, keratometry and computerized analysis of corneal topography.
Study: NCT02351258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 70% Isopropyl alcohol embedded caps
Description: Protective cap on central lines

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 70% Isopropyl alcohol embedded caps
Description: Protective cap on central lines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: This involves the Best Practice Central Line Maintenance Care Bundle which includes;~1. Daily assessment whether central line is needed~2. Central line Site Care~3. Central line Hub/Cap/Tubing Care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: This involves the Best Practice Central Line Maintenance Care Bundle which includes;~1. Daily assessment whether central line is needed~2. Central line Site Care~3. Central line Hub/Cap/Tubing Care
Study: NCT00430313

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electro-Stimulation of Yongquan (K1) Acupoint
Description: Electro-stimulation at an active (responsive) acupuncture site on the bottom of the foot.
Study: NCT02739035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg of IV dexamethasone immediately before MUA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 2 weeks per mouth of celecoxib (200 mg daily)
Study: NCT01336283

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training
Description: compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training
Description: compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined training
Description: compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined training
Description: compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
Study: NCT03839277

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff Vision
Description: Endocuff Vision is attached to the tip of colonoscope before intubation.
Study: NCT03955939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3295668 Erbumine
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3295668 Erbumine
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3295668 Erbumine
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3295668 Erbumine
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3295668 Erbumine
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Administered according to label instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Administered according to label instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Administered according to label instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally.
Study: NCT02809820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Patients randomized to this group will receive carvedilol at the highest dose tolerated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Patients randomized to this group will receive metoprolol at the highest dose tolerated
Study: NCT03451435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N acetyl cysteine
Description: N acetyl cysteine at 20mM will be utilized as the final stage of irrigation prior to induction of bleeding during endodontic revascularization procedure.
Study: NCT04025606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural
Description: Standard thoracic epidural (needle inserted into the space between the covering of spinal cord and the cord itself) preoperatively. Standard thoracic epidural analgesia mixture (2 mg/ ml bupivacaine, 2 µg/ ml fentanyl and 2 µg/ ml adrenalin) with an infusion of 6-10 ml/hour until day 2 postoperatively. Thereafter reduction by 30 % every four hours.